Skip to main content
Top
Published in: Clinical Rheumatology 5/2014

01-05-2014 | Original Article

Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis

Authors: Gábor Futó, Attila Somogyi, Zoltán Szekanecz

Published in: Clinical Rheumatology | Issue 5/2014

Login to get access

Abstract

There has been continuous debate regarding the applicability of various composite measures for the assessment of disease activity in rheumatoid arthritis (RA). In order to further dissect this issue, we numerically and graphically modeled 28-joint disease activity scale (DAS28), simplified disease activity index (SDAI), and clinical disease activity index (CDAI) by three-dimensional (3D) plotting. We wished to graphically visualize the relative contribution of various elements in the three activity indices to each other. We calculated DAS28 (3 variables), SDAI, and CDAI by the standard equations. We plotted 3D “carpets” showing all combinations of the corresponding variables yielding to DAS28 = 5.1, DAS28 = 3.2, DAS28 = 2.6, SDAI = 26, SDAI = 11, and SDAI = 3.3. We also plotted the 3D carpet for CDAI. In patients with high or moderate disease activity, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) was not a major confounding factor when calculating DAS28 and SDAI, respectively. In contrast, ESR and CRP highly overshadowed changes in joint counts and global assessments in patients with low disease activity (LDA) or those in remission. No reliable assessment of LDA can be performed in cases where ESR >54 mm/h or CRP >20 mg/dl. Similarly, remission cannot be determined if ESR >19 mm/h or CRP >5 mg/dl. As CDAI does not include acute phase reactants, CDAI may be a useful tool even in states of remission or LDA. Our results suggest that acute phase reactants are indeed major confounding factors and should be omitted when assessing RA disease activity at least in special cases.
Literature
1.
go back to reference Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204573 Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2013-204573
2.
go back to reference Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 59(10):1371–1377PubMedCrossRef Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 59(10):1371–1377PubMedCrossRef
3.
go back to reference van der Heijde DM, van‘t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49(11):916–920PubMedCrossRefPubMedCentral van der Heijde DM, van‘t Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49(11):916–920PubMedCrossRefPubMedCentral
4.
go back to reference van der Heijde DM, van‘t Hof M, van Riel PL, van de Putte LB (1993) Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20(3):579–581PubMed van der Heijde DM, van‘t Hof M, van Riel PL, van de Putte LB (1993) Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20(3):579–581PubMed
5.
go back to reference Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(5 Suppl 39):S100–S108PubMed Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(5 Suppl 39):S100–S108PubMed
6.
go back to reference Aletaha D, Smolen JS (2007) The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 21(4):663–675PubMedCrossRef Aletaha D, Smolen JS (2007) The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 21(4):663–675PubMedCrossRef
7.
go back to reference Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42(2):244–257CrossRef Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42(2):244–257CrossRef
8.
go back to reference Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):R796–R806PubMedCrossRefPubMedCentral Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):R796–R806PubMedCrossRefPubMedCentral
9.
go back to reference Salaffi F, Cimmino MA, Leardini G, Gasparini S, Grassi W (2009) Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI). Clin Exp Rheumatol 27(4):552–559PubMed Salaffi F, Cimmino MA, Leardini G, Gasparini S, Grassi W (2009) Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI). Clin Exp Rheumatol 27(4):552–559PubMed
10.
go back to reference Smolen JS, Aletaha D (2011) Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 63(1):43–52PubMedCrossRef Smolen JS, Aletaha D (2011) Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum 63(1):43–52PubMedCrossRef
11.
go back to reference Bentley MJ, Greenberg JD, Reed GW (2010) A modified rheumatoid arthritis disease activity score without acute-phase reactants (mDAS28) for epidemiological research. J Rheumatol 37(8):1607–1614PubMedCrossRef Bentley MJ, Greenberg JD, Reed GW (2010) A modified rheumatoid arthritis disease activity score without acute-phase reactants (mDAS28) for epidemiological research. J Rheumatol 37(8):1607–1614PubMedCrossRef
12.
go back to reference Rintelen B, Sautner J, Haindl PM, Andel I, Maktari A, Leeb BF (2009) Comparison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol 38(5):336–341PubMedCrossRef Rintelen B, Sautner J, Haindl PM, Andel I, Maktari A, Leeb BF (2009) Comparison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol 38(5):336–341PubMedCrossRef
13.
go back to reference Gaujoux-Viala C, Mouterde G, Baillet A, Claudepierre P, Fautrel B, Le Loet X, et al (2012) Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine 79(2):149–155 Gaujoux-Viala C, Mouterde G, Baillet A, Claudepierre P, Fautrel B, Le Loet X, et al (2012) Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine 79(2):149–155
14.
go back to reference Bentley MJ, Reed GW (2008) Simplified composite disease activity measures in rheumatoid arthritis: should they be used in standard care? Clin Exp Rheumatol 26(2):358–366PubMed Bentley MJ, Reed GW (2008) Simplified composite disease activity measures in rheumatoid arthritis: should they be used in standard care? Clin Exp Rheumatol 26(2):358–366PubMed
15.
go back to reference Dougados M, Schmidely N, Le Bars M, Lafosse C, Schiff M, Smolen JS et al (2009) Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis 68(4):484–489PubMedCrossRefPubMedCentral Dougados M, Schmidely N, Le Bars M, Lafosse C, Schiff M, Smolen JS et al (2009) Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis 68(4):484–489PubMedCrossRefPubMedCentral
16.
go back to reference Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964–975PubMedCrossRefPubMedCentral Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964–975PubMedCrossRefPubMedCentral
17.
go back to reference Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S et al (2008) Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59(1):32–41PubMedCrossRef Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S et al (2008) Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59(1):32–41PubMedCrossRef
18.
go back to reference Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631–637PubMedCrossRefPubMedCentral Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631–637PubMedCrossRefPubMedCentral
19.
go back to reference Aletaha D, Smolen JS (2011) Joint damage progresses in DAS28 remission and is driven by residual swollen joints. Arthritis Rheum. doi:10.1002/art.30634 Aletaha D, Smolen JS (2011) Joint damage progresses in DAS28 remission and is driven by residual swollen joints. Arthritis Rheum. doi:10.​1002/​art.​30634
Metadata
Title
Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis
Authors
Gábor Futó
Attila Somogyi
Zoltán Szekanecz
Publication date
01-05-2014
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 5/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2559-5

Other articles of this Issue 5/2014

Clinical Rheumatology 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine